Tolmar Pharmaceuticals, a fully integrated pharmaceutical company, through its affiliate, Tolmar, acquired of all rights to JATENZO from Clarus Therapeutics Holdings and its wholly-owned subsidiary Clarus Therapeutics. Following a competitive auction process, Tolmar was selected as the winning bidder in the sale of JATENZO (and certain related assets), and the sale was approved by the U.S. Bankruptcy Court for the District of Delaware.
RBC Capital Markets is acting as financial advisor and Faegre Drinker Biddle & Reath is acting as legal advisor to Tolmar in connection with the transaction.
“The addition of JATENZO to Tolmar’s robust portfolio further strengthens our position as a leader in urology and men’s health,” Anil D’Souza, president and CEO of Tolmar Pharmaceuticals. ” We have seen tremendous success in urology through our foundational therapy, ELIGARD, a market-leading product for advanced prostate cancer. This acquisition advances Tolmar’s overall business strategy, provides substantial growth potential and helps advance our mission to advocate for patients through our therapies. In addition, we are confident that adding JATENZO to the products promoted by our successful urology field sales force will lead to fast and more profitable growth for this differentiated product.”
“Hypogonadism affects each man differently, and JATENZO expands treatment options for patients and HCPs by offering a differentiated alternative to existing testosterone replacement therapies,” Todd Smith, president and chief commercial officer at Tolmar, said. “The acquisition of JATENZO is another milestone that solidifies Tolmar’s commitment to bringing forward therapies that improve healthcare experience as well as disease outcomes.”